Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 08:26 PM
September 2025
In this educational session, Becky Klemme, NP from Sioux Falls, South Dakota, shares over a decade of hepatology experience to highlight lifestyle management for patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Formerly known as NAFLD, MASLD is now the most common chronic liver disease worldwide, closely linked to obesity, type 2 diabetes, hypertension, and cardiovascular disease.
Through a detailed patient case, Becky explains how to evaluate MASLD using labs, imaging, and non-invasive tests like FIB-4 and FibroScan, and how to distinguish between simple steatosis, steatohepatitis (MASH), and advanced fibrosis. She outlines practical strategies for dietary changes, exercise, weight loss goals, and metabolic risk reduction—all while keeping patient-centered, culturally sensitive care in mind.
Viewers will also learn about the pathogenesis of MASLD and MASH, the role of genetics and lifestyle, and evidence-based approaches such as the Mediterranean diet, structured physical activity, behavioral counseling, and the 5A framework for patient engagement. With obesity and diabetes on the rise, early recognition and proactive lifestyle intervention are essential to preventing progression to cirrhosis, liver failure, or hepatocellular carcinoma (HCC).
If you are a hepatology provider, APP, or clinician managing patients with fatty liver disease, this session offers actionable insights and patient care strategies you can use in practice.
Related Podcast
Non-Invasive Testing With Brian Lam
August 2025
Join Brian Lam, PA-C, Associate Medical Director of Research at Inova’s Liver and Obesity Research Program and Chair of the Global NASH/MASH Council’s PA Committee, for a masterclass on non-invasive testing (NITs) in the evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH, presented through the GHAPP MASLD/MASH Community Network and sponsored by Madrigal Pharmaceuticals. In this dynamic and case-based session, Brian outlines a practical, step-by-step approach to identifying patients at risk for advanced fibrosis, using tools like FIB-4, ELF, FibroScan (VCTE), and MR Elastography. He walks through the critical cutoffs, diagnostic performance, limitations, and how to interpret imaging and lab-based scores in real-world hepatology and primary care settings. You'll learn how to apply AGA and AASLD clinical algorithms, the importance of staging patients with diabetes and metabolic syndrome, and how to distinguish low-risk MASLD from at-risk MASH. Brian also shares best practices for TE reliability, quality control, and using NIT combinations like FAST, MAST, and MEFIB for accurate diagnosis. With clear visuals, expert insights, and actionable takeaways, this session is an essential update for APPs, GI, hepatology, and primary care providers managing fatty liver disease in 2025 and beyond.
Watch Now
Misconceptions About Liver Health
July 2025
In this quick myth-busting session, Elizabeth Alqueza, PA-C from Beth Israel Deaconess Medical Center in Boston, addresses two of the most common misconceptions in hepatology related to steatotic liver disease (MASLD/MASH). First, she explains that liver disease is not always fixed or irreversible—and with proper management and elimination of the underlying cause, liver fibrosis can improve over time, a trend often monitored through FibroScan®. Second, she clarifies that significant liver improvement does not require extreme weight loss. In fact, a modest 5–10% reduction in total body weight—sometimes as little as 10–20 pounds—can lead to measurable improvements in liver inflammation and fibrosis. This video is ideal for providers and patients seeking a clearer understanding of how lifestyle changes can reverse liver disease and why timely, targeted interventions matter.
Watch Now
Addressing Health Disparities: Equity Considerations in MASH/MASLD Care
August 2025
Join Elizabeth Goacher, PA-C from Duke University Medical Center, for an in-depth discussion on addressing healthcare disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). As part of the MASLD Community Network, supported by Madrigal, Elizabeth explores how social determinants of health—including race, ethnicity, socioeconomic status, geography, and access to nutritious food—impact MASLD prevalence and outcomes. She highlights the higher rates of MASLD in Hispanic populations, individuals with obesity, diabetes, cardiovascular disease, and hypertension, and emphasizes actionable strategies clinicians can use in everyday practice to mitigate bias, improve screening, and provide equitable care. This episode underscores the importance of starting with the individual patient, asking the right questions, and tailoring recommendations based on access and resources to help reduce disparities and improve liver and metabolic health.
Watch Now
Lifestyle Management With Anthony Derencius
July 2025
Join Anthony Derencius, PA-C, at Pinnacle Clinical Research, for an in-depth, case-based discussion on the role of lifestyle management in MASH and MASLD. In this educational session from the GHAPP MASLD Community Network, Anthony walks through the real-world case of a 65-year-old patient with obesity, diabetes, and suspected metabolic liver disease, highlighting how to interpret non-invasive diagnostics like FIB-4 scores and transient elastography. He explains the clinical significance of metabolic risk factors, genetic predispositions (such as PNPLA3), and how personalized approaches to nutrition and exercise can alter the progression of fatty liver disease. With evidence-based insights on the Mediterranean diet, aerobic vs resistance training, and behavior change strategies, this video offers frontline strategies to support patients in reversing or slowing fibrosis. Watch to learn how providers can combine patient education, lifestyle interventions, and emerging pharmacotherapy to manage MASLD and MASH more effectively. Educational support provided by Madrigal Pharmaceuticals. For more disease state content, visit the GHAPP MASLD Community Network.
Watch Now
APP Insight: Misconceptions About Liver Health
June 2025
In this video, Kelly Smeester, PA-C from South Denver Gastroenterology, addresses some of the most common and harmful misconceptions about liver health. One major myth she tackles is the belief that liver disease only affects those who drink excessive amounts of alcohol. Kelly explains that liver disease has many causes—including autoimmune conditions, viral infections, and metabolic dysfunction—meaning even individuals who don’t drink at all may still be at risk. She emphasizes the dangers of relying on unregulated “liver detox” supplements, clarifying that the liver is a natural detox organ and doesn’t require external cleanses, which may actually do more harm than good. Kelly also highlights how liver disease can be entirely asymptomatic, particularly in patients with conditions like type 2 diabetes, obesity, hypertension, and high cholesterol. Finally, she reinforces that cirrhosis is not solely alcohol-related and can result from steatotic liver disease, making regular liver evaluations and screenings crucial for early detection and management. This video is an essential resource for patients and providers aiming to better understand liver health beyond outdated myths.
Watch Now
Comparing F3 and F4 Fibrosis With Allysa Saggese
September 2025
In this session from the MASLD/MASH Community Network, Allysa Saggese, NP from Weill Cornell Medicine in New York, explores the critical differences between F3 and F4 fibrosis through two detailed case studies. Accurate staging is essential in fatty liver disease management, as it directly impacts treatment decisions, eligibility for FDA-approved therapies like resmetirom, and the need for hepatocellular carcinoma (HCC) surveillance. Allysa explains how non-invasive tests such as FIB-4, FibroScan, ELF, CAP, and MRI elastography compare, when to consider a liver biopsy, and how to interpret discordant results. She also discusses treatment pathways, the role of GLP-1 receptor agonists, lifestyle modification, and monitoring strategies for patients with advanced fibrosis versus cirrhosis. This practical overview provides clinicians with a clear framework to distinguish between F3 and F4, ensuring patients receive timely interventions, surveillance, and education to improve long-term outcomes in MASLD/MASH.
Watch Now
MASLD vs MetALD With Janet Gripshover
September 2025
Janet Gripshover, NP, explains how to spot and manage metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH—now the preferred terms replacing NAFLD. Through a real patient case, she shows how ultrasound findings, everyday risk factors (PCOS, high blood pressure, cholesterol, higher BMI), and an honest alcohol history point the way. Janet covers easy, non-invasive tests (FIB-4 blood test, FibroScan® stiffness and CAP scores) and when alcohol biomarkers (PEth, urine EtG) help confirm what’s really driving the liver damage. You’ll learn simple next steps: Mediterranean-style eating, resistance exercise, weight loss goals, and complete alcohol cessation to prevent progression to cirrhosis. She also notes when to start liver cancer (HCC) screening and what to document in the chart. Perfect for APPs and clinicians looking for a clear, practical MASLD/MASH workflow.
Watch Now
Comparing F3 and F4 Fibrosis With Valerie Shin
September 2025
In this interactive case discussion, Valerie Shin, NP, from UCLA Health’s hepatology team, walks through how to compare F3 and F4 fibrosis in patients with metabolic dysfunction–associated steatohepatitis (MASH). Presented as part of the GHAPP MASLD Community Network series sponsored by Madrigal, this session uses real-world patient data to explore how non-invasive testing (NITs) like FibroScan, FIB-4, and ELF testing help stage liver fibrosis and guide treatment decisions. Valerie highlights the importance of accurate staging for prognosis, monitoring, and management—whether identifying patients with advanced fibrosis (F3) who may benefit from resmetirom (Rezdiffra), or recognizing progression to cirrhosis (F4) that requires enhanced surveillance and multidisciplinary care. This video also emphasizes practical strategies for lifestyle modification, metabolic risk factor control, and liver cancer screening. Whether you are a hepatology specialist, primary care provider, or advanced practice provider (APP), this case comparison offers valuable clinical insights into diagnosing and managing MASLD/MASH.
Watch Now
HCC Surveillance: Implementation in Patients with Advanced Fibrosis/Cirrhosis from MASH
July 2025
In this episode of the GHAPP MASLD Community Network podcast, Lisa Richards, a hepatology-focused nurse practitioner in San Diego, shares expert insights on hepatocellular carcinoma (HCC) surveillance for patients with advanced fibrosis and cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Lisa outlines which patients require routine HCC surveillance, emphasizing the importance of staging—particularly stages F3 and F4—and how AASLD guidelines guide surveillance strategies. She discusses recommended surveillance modalities, including ultrasound with AFP every six months, and introduces the LIRADS visualization score to help interpret imaging quality and follow-up needs. Lisa also addresses practical challenges in implementation, from patient education and engagement to overcoming barriers like cost, transportation, and care coordination. For advanced practice providers (APPs), this podcast delivers clear guidance on what to do when new liver lesions are detected and how to proceed with diagnostic imaging and referrals for multidisciplinary review or intervention. Empower your clinical practice with strategies that promote early detection and improve outcomes in patients at risk of HCC.
Watch Now
MASLD Basics With Maribeth Capuno
August 2025
Join us for an in-depth overview of steatotic liver disease, presented through the GHAPP MASLD/MASH Community Network and proudly sponsored by Madrigal Pharmaceuticals. This engaging session walks through the updated terminology replacing NAFLD and NASH with MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis)—explaining what the name change means and how to apply the latest AASLD 2023 guidelines in clinical practice. Learn how to identify MASLD based on cardiometabolic risk factors, rule out other causes of steatosis such as alcohol use, autoimmune conditions, and hereditary liver diseases, and determine when to use non-invasive testing like FIB-4, FibroScan, and ELF to stratify fibrosis risk. With Global Fatty Liver Day around the corner, this timely presentation also highlights the global burden of MASLD, its progression from steatosis to cirrhosis and HCC, and practical steps for primary care and hepatology teams to intervene early. You'll follow the case of JP, a 55-year-old with obesity, pre-diabetes, and elevated liver enzymes, as a real-world example of how to evaluate, diagnose, and manage MASLD—and when to refer to hepatology for advanced care. Whether you're a GI provider, APP, or primary care clinician, this talk offers a practical roadmap for managing fatty liver disease in 2025 and beyond.
Watch Now